Evidence of a novel aggrecan-degrading activity in cartilage: Studies of mice deficient in both ADAMTS-4 and ADAMTS-5

Arthritis and Rheumatism

Volumn 58, Issue 6, 2008, Pages 1664-1673

  Rogerson, Fraser M ^a   Stanton, Heather ^a   East, Charlotte J ^a   Golub, Suzanne B ^a   Tutolo, Leonie ^a   Farmer, Pamela J ^b   Fosang, Amanda J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE PROTEIN WITH THROMBOSPONDIN MOTIF 4; A DISINTEGRIN AND METALLOPROTEINASE PROTEIN WITH THROMBOSPONDIN MOTIF 5; AGGRECAN; AGGRECANASE; EPITOPE; INTERLEUKIN 1ALPHA; RETINOIC ACID;

ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CARTILAGE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SPECIFICITY; FEMUR HEAD; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SECRETION; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; AGGRECANS; ANIMALS; BLOTTING, WESTERN; CARTILAGE; ENDOPEPTIDASES; FEMUR HEAD; MICE; MICE, KNOCKOUT; PROCOLLAGEN N-ENDOPEPTIDASE;

EID: 45349087688     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23458     Document Type: Article

References (50)

1. Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage explants: identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266:8683-5.
2. Loulakis P, Shrikhande A, Davis G, Maniglia CA. N-terminal sequencing of proteoglycan fragments from medium of interleukin-1-treated articular-cartilage cultures: putative site(s) of enzyme cleavage. Biochem J 1992;284:589-93.
3. Ilic MZ, Handley CJ, Robinson HC, Mok MT. Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys 1992;294:115-22.
4. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest 1992;89:1512-6.
5. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993;36:1214-22.
6. Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L. Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase- derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem J 1995;310:337-43.
7. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-9.
8. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14:101-13.
9. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999;284:664-6.
10. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-50.
11. Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, et al. ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett 2000;478:241-5.
12. Collins-Racie LA, Flannery CR, Zeng W, Corcoran C, Annis-Freeman B, Agostino MJ, et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 2004;23:219-30.
13. Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem 2003;278:9503-13.
14. Zeng W, Corcoran C, Collins-Racie LA, LaVallie ER, Morris EA, Flannery CR. Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18. Biochim Biophys Acta 2006;1760:517-24.
15. Billington CJ, Clark IM, Cawston TE. An aggrecan-degrading activity associated with chondrocyte membranes. Biochem J 1998;336:207-12.
16. Hughes CE, Little CB, Buttner FH, Bartnik E, Caterson B. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem 1998;273:30576-82.
17. Arner EC, Hughes CE, Decicco CP, Caterson B, Tortorella MD. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage 1998;6:214-28.
18. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002;46:2648-57.
19. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007;56:575-85.
20. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001;9:539-52.
21. LaVallie ER, Chockalingam PS, Collins-Racie LA, Freeman BA, Keohan CC, Leitges M, et al. Protein kinase Cζ is up-regulated in osteoarthritic cartilage and is required for activation of NF-κB by tumor necrosis factor and interleukin-1 in articular chondrocytes. J Biol Chem 2006;281:24124-37.
22. Little CB, Hughes CE, Curtis CL, Jones SA, Caterson B, Flannery CR. Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum 2002;46:124-9.
23. Stanton H, Rogerson FM, East CJ, Golub SB, Little CB, Lawlor KE, et al. ADAMTS-5 is the major aggrecanase in mouse cartilage, in vivo and in vitro. Nature 2005;434:648-51.
24. East CJ, Stanton H, Golub SB, Rogerson FM, Fosang AJ. ADAMTS-5 deficiency blocks aggrecanase cleavage in the interglobular domain but not in the chondroitin sulfate-rich region of aggrecan. J Biol Chem 2007;282:8632-40.
25. Powell AJ, Little CB, Hughes CE. Low molecular weight isoforms of the aggrecanases are responsible for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system. Arthritis Rheum 2007;56:3010-9.
26. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002;277:22201-8.
27. Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol 2005;32:876-86.
28. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004;50:131-41.
29. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644-8.
30. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547-58.
31. Schmidt EE, Taylor DS, Prigge JR, Barnett S, Capecchi MR. Illegitimate Cre-dependent chromosome rearrangements in transgenic mouse spermatids. Proc Natl Acad Sci U S A 2000;97:13702-7.
32. Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005;52:1461-72.
33. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982;9:247-8.
34. Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns: evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 2000;275:33038-45.
35. Tortorella MD, Pratta MA, Liu RQ, Austin J, Ross OH, Abbaszade I, et al. Sites of aggrecan cleavage of recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000;275:18566-73.
36. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, et al. Aggrecan degradation in human cartilage: evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106.
37. Majumdar MK, Askew R, Schelling S, Stedman N, Blanchet T, Hopkins B, et al. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents progression of osteoarthritis. Arthritis Rheum 2007;56:3670-4.
38. Sandy JD, Thompson V, Doege K, Verscharen C. The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1. Biochem J 2000;351:161-6.
39. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001;358:615-26.
40. Tortorella MD, Liu RQ, Burn T, Newton RC, Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol 2002;21:499-511.
41. Pratta MA, Scherle PA, Yang G, Liu RQ, Newton RC. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003;48:119-33.
42. Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, et al. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol 2003;30:355-63.
43. Buckwalter JA, Rosenberg LC. Electron microscopic studies of cartilage proteoglycans: direct evidence for the variable length of the chondroitin sulfate-rich region of proteoglycan subunit core protein. J Biol Chem 1982;257:9830-9.
44. Paulsson M, Morgelin M, Wiedemann H, Beardmore-Gray M, Dunham D, Hardingham T, et al. Extended and globular protein domains in cartilage proteoglycans. Biochem J 1987;245:763-72.
45. Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE, Bayliss MT. Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J 1996;313:933-40.
46. Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteinases. J Biol Chem 1999;274:25555-63.
47. Little CB, Meeker CT, Hembry RM, Sims NA, Lawlor KE, Golub SB, et al. Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol Cell Biol 2005;25:3388-99.
48. 710 is present abundantly in human articular cartilage. J Biochem 2007;141:469-77.
49. Sztrolovics R, Recklies AD, Roughley PJ, Mort JS. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1β-stimulated catabolism. Biochem J 2002;362:473-9.
50. Ilic MZ, East CJ, Rogerson FM, Fosang AJ, Handley CJ. Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice. J Biol Chem 2007;282:37420-8.